New early-stage study of aducanumab adds to arsenal of strong data in Alzheimer's

US biotech major Biogen (Nasdaq: BIIB) is touting new data from the long-term extension (LTE) of its ongoing Phase Ib study of aducanumab, the company’s investigational treatment for Alzheimer’s disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting, Boston, November 1 – 4.

The data include results from patients in the Phase Ib study who were treated with a gradually increased dose of aducanumab for up to 24 months and those who were treated with a fixed dose of 3, 6 or 1mg/kg aducanumab for up to 36 months.

The results are consistent with previously reported analyses from the Phase Ib study and support the design of the ongoing Phase III studies of aducanumab for early Alzheimer’s disease, said Eisai. Phase III data for aducanumab is expected in late 2019 or early 2020.